Like aging machinery losing efficiency, reduced ELOVL2 activity hampers immune cell development. Researchers from UCSD and UC Irvine found that impaired enzyme function curbs B cell production. This discovery underscores the possibility of targeted lipid therapies to enhance immune resilience in older populations.
Q&A
- What is ELOVL2?
- How do reduced levels affect B cells?
- What therapies could address this issue?